DE60018601D1 - HBV/HCV Virus-ohnliche Particle - Google Patents

HBV/HCV Virus-ohnliche Particle

Info

Publication number
DE60018601D1
DE60018601D1 DE60018601A DE60018601A DE60018601D1 DE 60018601 D1 DE60018601 D1 DE 60018601D1 DE 60018601 A DE60018601 A DE 60018601A DE 60018601 A DE60018601 A DE 60018601A DE 60018601 D1 DE60018601 D1 DE 60018601D1
Authority
DE
Germany
Prior art keywords
virus
particles
hbv
chimeric antigens
hepatitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60018601A
Other languages
English (en)
Other versions
DE60018601T2 (de
DE60018601T4 (de
Inventor
Mark Selby
Edward Glazer
Michael Houghton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Application granted granted Critical
Publication of DE60018601D1 publication Critical patent/DE60018601D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
DE60018601A 1999-11-24 2000-11-22 HBV/HCV Virus-ohnliche Particle Expired - Lifetime DE60018601D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16722499P 1999-11-24 1999-11-24
PCT/US2000/032249 WO2001038358A2 (en) 1999-11-24 2000-11-22 Hbv/hcv virus-like particle

Publications (1)

Publication Number Publication Date
DE60018601D1 true DE60018601D1 (de) 2005-04-14

Family

ID=22606465

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60018601T Expired - Lifetime DE60018601T4 (de) 1999-11-24 2000-11-22 HBV/HCV Virus-ähnliche Partikel
DE60018601A Expired - Lifetime DE60018601D1 (de) 1999-11-24 2000-11-22 HBV/HCV Virus-ohnliche Particle

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE60018601T Expired - Lifetime DE60018601T4 (de) 1999-11-24 2000-11-22 HBV/HCV Virus-ähnliche Partikel

Country Status (8)

Country Link
EP (1) EP1233783B9 (de)
JP (1) JP4647870B2 (de)
AT (1) ATE290399T1 (de)
AU (1) AU1928201A (de)
CA (1) CA2392527C (de)
DE (2) DE60018601T4 (de)
ES (1) ES2430368T3 (de)
WO (1) WO2001038358A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1450856B1 (de) * 2001-09-14 2009-11-11 Cytos Biotechnology AG VERPACKUNG VON IMMUNSTIMULIERENDEM CpG IN VIRUSÄHNLICHEN PARTIKELN: HERSTELLUNGSVERFAHREN UND VERWENDUNG
WO2003066841A1 (en) * 2002-02-07 2003-08-14 Melbourne Health Viral variants with altered susceptibility to nucleoside analogs and uses thereof
DE10218129A1 (de) * 2002-04-23 2003-11-20 Univ Ruprecht Karls Heidelberg Genetischer Impfstoff gegen RNA-Virus-Infektionen
WO2004110482A1 (en) * 2003-06-13 2004-12-23 Isis Innovation Limited Improved vaccines
EP1973608A1 (de) 2005-12-14 2008-10-01 Cytos Biotechnology AG Immunstimulatorische nukleinsäure-packteilchen zur behandlung von überempfindlichkeit
AU2007260236B2 (en) 2006-06-12 2013-05-16 Kuros Us Llc Processes for packaging oligonucleotides into virus-like particles of RNA bacteriophages
US20080166785A1 (en) * 2006-08-16 2008-07-10 Monica Sala-Schaeffer Polynucleotides allowing the expression and secretion of recombinant HBsAg virus-like particles containing a foreign peptide, their production and use
CA2671873C (en) 2006-12-12 2018-10-09 Brian Stephen Sproat Oligonucleotides containing high concentrations of guanine monomers
FR2932388B1 (fr) * 2008-06-17 2013-03-29 Univ Rabelais Francois Nouvelles proteines de fusion et leur application pour la preparation de vaccins contre l'hepatite c
US9238679B2 (en) * 2011-02-11 2016-01-19 The Trustees Of The University Of Pennslyvania Nucleic acid molecule encoding hepatitis B virus core protein and surface antigen protein and vaccine comprising the same
JP2014212722A (ja) * 2013-04-24 2014-11-17 学校法人加計学園 八面体構造を有するｂ型肝炎ウイルス様粒子結晶
EA202091513A1 (ru) 2017-12-19 2020-09-09 Янссен Сайенсиз Айрлэнд Анлимитед Компани Вакцины против вируса гепатита b (hbv) и их применение
WO2022133230A1 (en) * 2020-12-18 2022-06-23 Janssen Pharmaceuticals, Inc. Combination therapy for treating hepatitis b virus infection

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5098704A (en) * 1984-06-18 1992-03-24 Chiron Corporation Hepatitis surface antigen particle vaccine
FR2581394B1 (fr) * 1985-05-02 1988-08-05 Grp Genie Genetique Particules ayant les proprietes immunogenes de l'antigene hbs et portant un site antigenique etranger aux epitopes portes par l'antigene hbs, vecteurs et cellules animales pour la production de telles particules et compositions contenant de telles particules pour la production de vaccins mixtes
KR970010787A (ko) * 1995-08-14 1997-03-27 성재갑 B형 간염 바이러스 표면항원과 c형 간염 바이러스 외피 단백질의 융합 단백질 및 이를 포함하는 혼합 백신

Also Published As

Publication number Publication date
ES2430368T3 (es) 2013-11-20
ATE290399T1 (de) 2005-03-15
EP1233783B9 (de) 2006-03-15
JP2003514576A (ja) 2003-04-22
CA2392527C (en) 2013-09-10
CA2392527A1 (en) 2001-05-31
DE60018601T2 (de) 2006-03-09
WO2001038358A3 (en) 2002-01-10
EP1233783A2 (de) 2002-08-28
JP4647870B2 (ja) 2011-03-09
DE60018601T4 (de) 2008-05-21
WO2001038358A2 (en) 2001-05-31
EP1233783B1 (de) 2005-03-09
AU1928201A (en) 2001-06-04
WO2001038358A9 (en) 2002-06-27

Similar Documents

Publication Publication Date Title
DE60018601D1 (de) HBV/HCV Virus-ohnliche Particle
Speidel et al. Priming of cytotoxic T lymphocytes by five heat‐aggregated antigens in vivo: conditions, efficiency, and relation to antibody responses
BR0113307A (pt) Molécula de proteìna quimérica de núcleo de vìrus de hepatite b recombinante, partìcula imunogênica, vacina ou inóculo, ácido nucleico, molécula de ácido nucleico recombinante, célula hospedeira e método de induzir uma resposta imunológica em um animal hospedeiro inoculado
MXPA05009289A (es) Conjugados de particulas tipo virus del analogo del peptido melan-a.
Tang et al. A modular vaccine development platform based on sortase-mediated site-specific tagging of antigens onto virus-like particles
WO2002009645A3 (en) Intercellular transport protein linked to an antigen as a molecular vaccine
CA2405438A1 (en) Hepatitis b core antigen fusion proteins
RU2008106445A (ru) Вирусоподобные корпускулы (частицы) в качестве противопарамиксовирусной вакцины
WO2003068933A3 (en) Optimization of gene sequences of virus-like particles for expression in insect cells
KR880009130A (ko) 간염 b 바이러스 표면항원 및 이를 함유하는 하이브리드 항원
ES2170622A1 (es) Clones y vectores infectivos derivados de coronavirus y sus aplicaciones.
Mihailova et al. Recombinant virus-like particles as a carrier of B-and T-cell epitopes of hepatitis C virus (HCV)
KR880701283A (ko) Aids의 원인이 되는 비루스의 당단백질을 암호화하는 비루스 벡터, 백신 및 항체
DK1119630T3 (da) Nukleinsyrekonstruktioner til genetisk immunisering
WO2005021713A3 (en) Vectors expressing sars immunogens, compositions containing such vectors or expression products thereof, methods and assays for making and using
Akhras et al. Cell-permeable capsids as universal antigen carrier for the induction of an antigen-specific CD8+ T-cell response
CY1107431T1 (el) Σωματιδια για γoνιδιακη θεραπεια
Rueda et al. Influence of flanking sequences on presentation efficiency of a CD8+ cytotoxic T-cell epitope delivered by parvovirus-like particles
JP2003514576A5 (de)
Grabherr et al. The baculovirus expression system as a tool for generating diversity by viral surface display
MY157396A (en) Novel fusion proteins and use thereof for preparing hepatitis c vaccines
Osamu et al. Purification of hepatitis B virus gene X product synthesized in Escherichia coli and its detection in a human hepatoblastoma cell line producing hepatitis B virus
Köck et al. Duck hepatitis B virus nucleocapsids formed by N-terminally extended or C-terminally truncated core proteins disintegrate during viral DNA maturation
EP1535628A3 (de) HBV/HCV Virus-ähnliche Teilchen
WO2006112929A3 (en) The hiv gp-41-membrane proximal region arrayed on hepatitis b surface antigen particles as novel antigens

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS,INC.(N.D.GES, US